JP2022533949A - 高濃度細胞のパッケージングおよび輸送 - Google Patents
高濃度細胞のパッケージングおよび輸送 Download PDFInfo
- Publication number
- JP2022533949A JP2022533949A JP2021568118A JP2021568118A JP2022533949A JP 2022533949 A JP2022533949 A JP 2022533949A JP 2021568118 A JP2021568118 A JP 2021568118A JP 2021568118 A JP2021568118 A JP 2021568118A JP 2022533949 A JP2022533949 A JP 2022533949A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- therapeutic composition
- cell
- therapeutic
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004806 packaging method and process Methods 0.000 title claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 47
- 210000004027 cell Anatomy 0.000 claims description 242
- 239000000203 mixture Substances 0.000 claims description 62
- 210000004700 fetal blood Anatomy 0.000 claims description 58
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 46
- 239000003937 drug carrier Substances 0.000 claims description 25
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 23
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 210000005087 mononuclear cell Anatomy 0.000 claims description 16
- 238000003860 storage Methods 0.000 claims description 14
- 230000003169 placental effect Effects 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 230000035899 viability Effects 0.000 claims description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 7
- 229940050410 gluconate Drugs 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 4
- 108010071390 Serum Albumin Proteins 0.000 claims description 4
- 210000000601 blood cell Anatomy 0.000 claims description 4
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- 210000002798 bone marrow cell Anatomy 0.000 claims description 3
- 210000004976 peripheral blood cell Anatomy 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000000176 sodium gluconate Substances 0.000 claims description 3
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 210000001912 transporting cell Anatomy 0.000 claims 1
- 150000004684 trihydrates Chemical class 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 11
- 238000002659 cell therapy Methods 0.000 abstract description 3
- 210000000130 stem cell Anatomy 0.000 description 76
- 239000000243 solution Substances 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 210000003743 erythrocyte Anatomy 0.000 description 26
- 230000032258 transport Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 230000003204 osmotic effect Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 7
- -1 polytetrafluoroethylene Polymers 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 238000011109 contamination Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 229920001774 Perfluoroether Polymers 0.000 description 5
- 102100040120 Prominin-1 Human genes 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000005138 cryopreservation Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 5
- 239000004810 polytetrafluoroethylene Substances 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 239000003761 preservation solution Substances 0.000 description 5
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 4
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000011712 cell development Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011018 current good manufacturing practice Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229920001684 low density polyethylene Polymers 0.000 description 4
- 239000004702 low-density polyethylene Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229920009441 perflouroethylene propylene Polymers 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 102100037917 CD109 antigen Human genes 0.000 description 3
- 102100024210 CD166 antigen Human genes 0.000 description 3
- 102100022002 CD59 glycoprotein Human genes 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 101000738399 Homo sapiens CD109 antigen Proteins 0.000 description 3
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 3
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 3
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 3
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 3
- 102100039564 Leukosialin Human genes 0.000 description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000008151 electrolyte solution Substances 0.000 description 3
- 239000012997 ficoll-paque Substances 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229940081860 plasma-lyte 148 Drugs 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010020852 Hypertonia Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011127 biaxially oriented polypropylene Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000002977 intracellular fluid Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000005026 oriented polypropylene Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 239000009719 polyimide resin Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 238000013190 sterility testing Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000003014 totipotent stem cell Anatomy 0.000 description 2
- 229920001862 ultra low molecular weight polyethylene Polymers 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000033197 Genetic hemoglobinopathy Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000008010 Tooth Avulsion Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- JCLHQFUTFHUXNN-UHFFFAOYSA-N ethyl biscoumacetate Chemical compound C1=CC=C2OC(=O)C(C(C=3C(OC4=CC=CC=C4C=3O)=O)C(=O)OCC)=C(O)C2=C1 JCLHQFUTFHUXNN-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004523 ligament cell Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012010 media fill test Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000002444 unipotent stem cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
この出願は、2019年5月15日に提出された米国仮出願第62/848,230号の優先権を主張する。本出願の内容は、その全体が参照により本明細書に組み込まれる。
本発明の一態様は、治療用細胞組成物に関する。組成物は、(i)約1×107~1×109/mlの治療用細胞と、(ii)薬学的に許容される担体溶液とを含む。薬学的に許容される担体溶液は、(a)約25~30mM(例えば、26~28mMおよび27mM)の酢酸塩および約20~25mM(例えば、21~24mMおよび23mM)のグルコン酸塩を含み、(b)約270~320mOsmol/Lの重量モル浸透圧濃度(例えば、280~310、290~300および約294または295mOsmol/L)を有する。
様々な幹細胞または多能性細胞を使用して、本発明を実施することができる。細胞の例には、臍帯血細胞、造血幹細胞、胚性幹細胞、骨髄幹細胞、末梢血幹細胞、胎盤血、および機能細胞、例えば神経細胞またはグリア細胞に分化することができる他の幹細胞が含まれる。本発明のそのような治療用細胞は、骨髄、臍帯血、臍帯、ウォートンゼリー、末梢血、リンパ組織、子宮内膜、栄養芽細胞由来組織、胎盤、羊膜液、脂肪組織、筋肉、肝臓、軟骨、神経組織、心臓組織、歯髄組織、剥離した歯、胚性幹(ES)細胞もしくは人工多能性幹(iPS)細胞に由来する細胞、またはそれらの任意の組み合わせから単離または得ることができる。
造血幹細胞は多能性であり、最終的にはすべてのタイプの最終分化した血液細胞を生じさせる。造血幹細胞は、自己複製するか、よりコミットされた前駆細胞に分化することができ、前駆細胞は、たった数種類の血液細胞の祖先であると不可逆的に決定される。例えば、造血幹細胞は、(i)骨髄前駆細胞に分化することができ、骨髄前駆細胞は最終的に、単球およびマクロファージ、好中球、好塩基球、好酸球、赤血球、巨核球/血小板、樹状細胞、を生じさせ、または(ii)リンパ球前駆細胞に分化することができ、リンパ球前駆細胞は最終的に、T細胞、B細胞、およびナチュラルキラー細胞(NK細胞)と呼ばれるリンパ球様細胞を生じさせる。幹細胞が骨髄系前駆細胞に分化すると、その子孫はリンパ系の細胞を生じさせることができず、同様に、リンパ系前駆細胞は骨髄系の細胞を生じさせることができない。造血および造血幹細胞の分化に関する一般的な議論については、Chapter 17,Differentiated Cells and the Maintenance of Tissues,Alberts et al.,1989,Molecular Biology of the Cell,2nd Ed.,Garland Publishing,New York,N.Y.、Regenerative Medicine,Department of Health and Human Services,August 2006の第2章、およびHematopoietic Stem Cells,2009,Stem Cell Information,Department of Health and Human Servicesの第5章を参照されたい。
ヒト臍帯血および/またはヒト胎盤血は、臍帯血幹細胞の供給源である。そのような血液は、当技術分野で知られている任意の方法によって得ることができる。幹細胞の供給源として臍帯血または胎盤血を使用することは、臍帯血または胎盤血がドナーへの外傷なしに容易に得られることを含む多くの利点を提供する。例えば、米国特許第5,004,681号および米国特許第7,147,626を参照されたい。収集は無菌条件下で行うべきである。採取後すぐに、臍帯血または胎盤血の液を抗凝固剤と混合することができる。そのような抗凝固剤は、CPD(クエン酸リン酸デキストロース)、ACD(酸性クエン酸デキストロース)、オルシーバー液(Alsever et al.,1941,N.Y.St.J.Med.41:126)、De Gowin液(De Gowin,et al.,1940,J.Am.Med.Ass.114:850)、Edglugate-Mg(Smith,et al.,1959,J.Thorac.Cardiovasc.Surg.38:573)、Rous-Turner溶液(Rous and Turner,1916,J.Exp.Med.23:219)、他のグルコース混合物、ヘパリン、ビスクマ酢酸エチルなどを含む、当技術分野で知られているものであればどれでもよい。例えば、Hum,1968,Storage of Blood,Academic Press,New York,pp.26-160を参照されたい)。臍帯血は、臍帯からの直接排液および/または娩出された胎盤の根および膨張した静脈からの針吸引によって得ることができる。一般的に、米国特許第5,004,681号を参照されたい。
本明細書に記載の治療用組成物は、約25~30mM(例えば、26~28mMおよび27mM)の酢酸塩および約20~25mM(例えば、21~24mMおよび23mM)のグルコン酸塩を含む薬学的に許容される担体または保存溶液を含み、(b)は重量モル浸透圧濃度が約270~320mOsmol/L(例えば、約280~310、280~300、290~300、294、または295mOsmol/L)である。
別の局面において、本発明は、高濃度で長期間にわたって、室温または周囲温度などの条件下で、上記の治療用幹細胞または調製物をパッケージングおよび/または輸送することに関する。予想外にも、このようにパッケージングされて輸送された細胞および調製物は、臨床使用のための満足のいく生存率および発生の可能性を有していた。
移植と分析のために十分な生細胞がなければならない。好ましくは、細胞を分析するのに十分な残りの細胞が存在するように、移植(例えば、脊髄への)に必要な細胞の数の少なくとも2倍が好ましい。輸送に含まれる細胞が少ない場合、その輸送は移植に適していないはずである。
調製物中に死んだ細胞が多すぎることは避けるべきである。この目的のために、トリパンブルー排除(TBE)を使用した手動カウントを生存率の基準として使用できる。パーセンテージで表される細胞懸濁液のTBEは、青色に染色されていない細胞を染色された細胞と染色されていない細胞の総数で割ったものである。移植用に指定された細胞の場合、TBEは少なくとも70%である必要がある。一般に、以下の実施例で説明する洗浄手順では、死んだ細胞が排除され、細胞懸濁液は通常、移植直前に90%を超えるTBEを示す。
汚染の証拠またはリスクはすべて報告されるべきである。これには、例えば、輸送用バッグ内の液体の漏れの存在、細胞懸濁液の異常な濁り、顕微鏡下で見える細菌または真菌、または以前の汚染の報告が含まれる。本明細書に開示されるように、母体のB型肝炎コア抗原に陽性である臍帯血単位、ならびに通常は臍帯血単位を国立骨髄ドナープログラム(NMDP)の下での登録から除外する他のすべての感染性病原体を除外するように注意を払うべきである。
最終的な調製物は95%以上の単核細胞を有するべきである。細胞の生存率カウントが5%以上の赤血球または好中球などの他の細胞を示している場合、その細胞は移植に使用されないであろう。臍帯血には未熟な赤い有核細胞が存在する可能性があることに注意されたい。
本発明の実施形態はまた、米国FDAまたは米国以外の国における同等の規制当局によって施行されるcGMP規制の下で治療用細胞を製造、貯蔵、または輸送する可能性の商業的提供に関する。治療用細胞および組成物は、様々な疾患および障害を治療するために有用である。障害の例には、変性疾患、虚血状態(例えば、肢虚血、うっ血性心不全、心臓虚血、腎臓虚血およびESRD、脳卒中、および眼の虚血)、器官または組織の再生を必要とする状態(例えば、肝臓、膵臓、肺、唾液腺、血管、骨、皮膚、軟骨、腱、靭帯、脳、毛、腎臓、筋肉、心筋、神経、および肢の再生)、炎症性疾患(例えば、心臓疾患、糖尿病、脊髄損傷、関節リウマチ、骨関節炎、人口股関節置換または修正による炎症、クローン病、および移植片対宿主疾患)自己免疫疾患(例えば、1型糖尿病、乾癬、全身性ループス、および多発性硬化症)、貧血、好中球減少症、血小板減少症、骨髄増殖性障害または血液新生物などの先天性疾患の血液学的障害、ならびに白血病およびリンパ腫などのがんが含まれるが、これらに限定されない。
本明細書で使用される場合、「治療用細胞」は、患者の状態、疾患、および/または損傷を改善する細胞集団を指す。治療用細胞は、自家(すなわち、患者に由来する)、同種異系(すなわち、患者とは異なる同じ種の個体に由来する)、または異種(すなわち、患者とは異なる種に由来する)であり得る。治療用細胞は、同種(すなわち、単一の細胞型からなる)または異種(すなわち、複数の細胞型からなる)であり得る。「治療用細胞」という用語は、治療的に活性な細胞と、治療的に活性な細胞に分化することができる前駆細胞の両方を含む。
この実施例は、凍結されたSTEMCYTE臍帯血液単位(UCBU)から新たに収集または解凍された臍帯血細胞をパッケージングするための例示的な手順を説明する。手短に言えば、臍帯血細胞は、当技術分野で知られている標準的な方法を使用して収集された。あるいは、凍結UCBCの1つ以上のバッグを、参照によりその全体が組み込まれるWO2012/112572に記載された手順に従って解凍した。次に、細胞を、血液溶解物手順またはWO2012/112572に記載されているMNC単離手順のいずれかに供した。次に、細胞を、約1%のHASを含む薬学的に許容される担体/保存溶液と混合した。ここで使用された2つの薬学的に許容される担体/保存溶液は生理食塩水およびPLASMA-LYTE Aであった。細胞の濃度は約1x109/mlに調整された。このようにパッケージングされた細胞は、室温または4℃で、12時間から96時間(4日)の期間にわたって別の場所に輸送された。
この実施例では、アッセイを実施して、上記の実施例1に記載された方法でパッケージングおよび輸送された細胞を検査した。簡単に説明すると、細胞パッケージは、WO2012/112572に記載されている方法で検査および開梱された。細胞生存率アッセイ、UCB-MNCの細胞数、およびCFUアッセイは、WO2012/112572に記載されている方法で実施した。結果を図1A~1Dに示す。
Claims (23)
- (i)約1×107~1×109/mlの治療用細胞と、(ii)(a)約25~30mMの酢酸塩および約20~25mMのグルコン酸塩を含有し、(b)重量モル浸透圧濃度が約270~320mOsmol/Lである薬学的に許容される担体溶液と、を含む、治療用組成物。
- 前記薬学的に許容される担体溶液が、約120~160mMのNa+、約3~7mMのK+、約1.0~2.0mMのMg2+、および約90~110mMのCl-、のうちの1つ以上を含有する、請求項1に記載の治療用組成物。
- 前記薬学的に許容される担体溶液が、Ca2+もしくは乳酸塩、またはそれらの両方を含まない、請求項2に記載の治療用組成物。
- 前記薬学的に許容される担体溶液が、約140mMのNa+、約5mMのK+、約1.5mMのMg2+、約98mMのCT、約27mMの酢酸塩、および約23mMのグルコン酸塩を含有する、請求項1~3のいずれか一項に記載の治療用組成物。
- 前記薬学的に許容される担体溶液が、約90mMの塩化ナトリウム(NaCl)、約5mMの塩化カリウム(KCl)、約1.5mMの塩化マグネシウム(MgCl2・6H2O)、約27mMの酢酸ナトリウム三水和物(C2H3NaO2.3H2O)、および約23mMのグルコン酸ナトリウム(C6H11NaO7)を含有する、請求項4に記載の治療用組成物。
- 前記薬学的に許容される担体溶液が、126~154mEq/Lのナトリウムを有する、請求項1に記載の治療用組成物。
- 前記薬学的に許容される担体溶液が、5.5~8.0のpHを有する、請求項1~6のいずれか一項に記載の治療用組成物。
- 前記治療用組成物が、DMSOを含まないか、または微量のDMSOを含有する、請求項1~7のいずれか一項に記載の治療用組成物。
- 前記治療用組成物が、約1×108/mlの治療用細胞を含有する、請求項1~8のいずれか一項に記載の治療用組成物。
- 前記治療用細胞が単核細胞を含む、請求項1~9のいずれか一項に記載の治療用組成物。
- 前記細胞が、臍帯血細胞、造血幹細胞、間葉系幹細胞、胚性幹細胞、末梢血細胞、骨髄細胞、または胎盤血細胞を含む、請求項10に記載の治療用組成物。
- 前記細胞が、CD13+、CD34+、またはCD134+細胞を含む、請求項1~11のいずれか一項に記載の治療用組成物。
- 前記治療用組成物が、約0.5%~約5%の血清または血清アルブミンを含有する、請求項1~12のいずれか一項に記載の治療用組成物。
- 前記血清または血清アルブミンが、ヒト血清またはヒト血清アルブミンである、請求項13に記載の治療用組成物。
- 前記組成物が、約1~10℃、約2~8℃、または約3~5℃の範囲内の温度を有する、請求項1~14のいずれか一項に記載の治療用組成物。
- 前記組成物が約4℃の温度を有する、請求項15に記載の治療用組成物。
- 請求項1~16のいずれか一項に記載の組成物と、
前記組成物を保持し、基材を含む容器であって、前記基材がポリマーを含む容器と、を含む、パッケージング製品。 - 前記容器が、バッグ、チューブ、シリンジ、または注射器用のバイアルである、請求項17に記載のパッケージング製品。
- 前記容器が封止されている、請求項17または18に記載のパッケージング製品。
- 細胞を貯蔵または輸送するための方法であって、(i)請求項1~19のいずれか一項に記載の治療用組成物またはパッケージング製品を準備することと、(ii)前記組成物を、1~10℃の範囲内の温度で約24~96時間貯蔵または輸送することと、を含む、方法。
- 前記細胞が単核細胞を含む、請求項20に記載の方法。
- 前記貯蔵または輸送した後、前記細胞は、
30CFU/3x104細胞超を形成すること、
回収率が40%超であるか、または生存率が40%超であること、のうちの1つ以上が可能である、請求項20または21に記載の方法。 - 前記治療用組成物が、約72時間貯蔵または輸送される、請求項20~22のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962848230P | 2019-05-15 | 2019-05-15 | |
US62/848,230 | 2019-05-15 | ||
PCT/US2020/032433 WO2020231968A1 (en) | 2019-05-15 | 2020-05-12 | High concentration cell packaging and shipping |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022533949A true JP2022533949A (ja) | 2022-07-27 |
Family
ID=73289250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021568118A Pending JP2022533949A (ja) | 2019-05-15 | 2020-05-12 | 高濃度細胞のパッケージングおよび輸送 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220175674A1 (ja) |
EP (1) | EP3968992A4 (ja) |
JP (1) | JP2022533949A (ja) |
CN (1) | CN113811295A (ja) |
CA (1) | CA3137570A1 (ja) |
TW (1) | TW202110463A (ja) |
WO (1) | WO2020231968A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023190640A1 (ja) * | 2022-03-30 | 2023-10-05 | 株式会社カネカ | 細胞投与用シリンジを調製する方法、及び細胞投与用シリンジを用いた細胞輸送方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955257A (en) * | 1997-10-21 | 1999-09-21 | Regents Of The University Of Minnesota | Infusible grade short-term cell storage medium for mononuclear cells |
US8114668B2 (en) * | 2007-05-14 | 2012-02-14 | Cardiac Pacemakers, Inc. | Composition for cold storage of stem cells |
MX2011001730A (es) * | 2008-08-14 | 2011-03-24 | Osiris Therapeutics Inc | Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales. |
CA2827590C (en) * | 2011-02-18 | 2020-09-01 | Stemcyte, Inc. | Stem cells packaging and shipping |
AU2012250794B2 (en) * | 2011-05-03 | 2015-11-05 | Immunovative Therapies, Ltd. | Methods for handling biological drugs containing living cells |
PT2729562T (pt) * | 2011-07-06 | 2018-07-18 | Cell Therapy Ltd | Células progenitoras de linhagem mesodérmica |
US20130216495A1 (en) * | 2012-02-21 | 2013-08-22 | Baxter Healthcare Sa | Pharmaceutical composition comprising cd34+ cells |
CN104542578B (zh) * | 2015-02-05 | 2017-01-18 | 广州赛莱拉干细胞科技股份有限公司 | 一种细胞保存液及其制备方法、应用 |
WO2017058819A1 (en) * | 2015-10-02 | 2017-04-06 | The Regents Of The University Of California | Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke |
CR20180503A (es) * | 2016-04-14 | 2018-12-21 | Hutchinson Fred Cancer Res | Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos |
CN106922648A (zh) * | 2017-02-22 | 2017-07-07 | 海南新生命干细胞医疗有限公司 | 一种间充质干细胞低温保存液及其制备方法 |
CN108378021A (zh) * | 2018-03-19 | 2018-08-10 | 英普乐孚生物技术(上海)有限公司 | 一种淋巴细胞冷藏保存体系 |
-
2020
- 2020-05-12 CN CN202080033505.1A patent/CN113811295A/zh active Pending
- 2020-05-12 WO PCT/US2020/032433 patent/WO2020231968A1/en unknown
- 2020-05-12 TW TW109115712A patent/TW202110463A/zh unknown
- 2020-05-12 JP JP2021568118A patent/JP2022533949A/ja active Pending
- 2020-05-12 CA CA3137570A patent/CA3137570A1/en active Pending
- 2020-05-12 EP EP20806830.4A patent/EP3968992A4/en active Pending
- 2020-05-12 US US17/611,241 patent/US20220175674A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202110463A (zh) | 2021-03-16 |
EP3968992A1 (en) | 2022-03-23 |
EP3968992A4 (en) | 2023-06-21 |
WO2020231968A1 (en) | 2020-11-19 |
CN113811295A (zh) | 2021-12-17 |
US20220175674A1 (en) | 2022-06-09 |
CA3137570A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0343217B1 (en) | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood | |
US6277557B1 (en) | Infusible grade short-term cell storage medium | |
US5192553A (en) | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use | |
JP6853081B2 (ja) | Hlaの適合なしに造血機能を提供するための組成物および方法 | |
JP5998265B2 (ja) | トレハロース及びデキストラン含有哺乳動物細胞移植用溶液 | |
Ademokun et al. | Umbilical cord blood collection and separation for haematopoietic progenitor cell banking | |
US20120093782A1 (en) | Enhanced Hematopoietic Stem Cell Engraftment | |
JP5899246B2 (ja) | 幹細胞の包装製品並びに同包装製品を作製する方法および輸送する方法 | |
JP6531256B2 (ja) | 臍帯血および末梢血の凍結保存方法および凍結保存用溶液 | |
AU2009228141A1 (en) | Mehtod, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue | |
Winter et al. | Long-term effects of cryopreservation on clinically prepared hematopoietic progenitor cell products | |
US20220175674A1 (en) | High concentration cell packaging and shipping | |
Murphy et al. | In vitro aspects of erythropoiesis | |
Kletzel et al. | Red cell depletion of umbilical cord blood (UCB): comparison between unmanipulated and red cell-depleted UCB by Ficoll-Paque density gradient separation | |
Rebulla et al. | Umbilical Cord Blood as a Source of Novel Reagents and Therapeutics | |
Bayer-Zwirello et al. | The effect of processing and cryopreservation on nucleated umbilical cord blood cells | |
Filip et al. | Homing of lin−/CD117+ hematopoietic stem cells | |
Veronesi et al. | cGMP-compliant transportation conditions for a prompt therapeutic use of marrow mesenchymal stromal/stem cells | |
Jahan | Impact of storage and cryoprotectants on the function of cord blood hematopoietic stem cells | |
McCullough | Hematopoietic stem cells and cord blood | |
Fergany | Faculty of Biotechnology Research Project RS400 (Pre-Cryopreservation Umbilical Cord Blood quality: The significance of Gestational age and | |
Aroviita | Cord blood haematopoietic stem cell units for transplantation | |
EP3765600A1 (en) | Cell products with improved stability and uses thereof | |
AlMulhem | Cryopreservation and Hypothermal Storage of Hematopoietic Stem Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230207 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240326 |